{"prompt": "['14', 'A pre-specified sub-group analysis will be performed on subjects', 'with pain scores > 5 as well as subjects with A1C above and', 'below 8.5.', 'All hypothesis tests comparing active and sham treatment will be', 'two-sided and conducted at the 5% significance level based on', 'Part A of the study. The primary population for assessing', 'efficacy and safety will be the ITT population from Part A.', 'A', 'secondary analysis of the individual efficacy endpoints will be', 'conducted using the Per-Protocol population from Part A. All', 'summary tables will be presented by treatment group and over all', 'patients in the analysis population being summarized.', 'Continuous variables will be summarized using the following', 'descriptive statistics: n, mean, SD, median, minimum, and', 'maximum. Categorical variables will be summarized using', 'counts and percentages. Percentages presented will be calculated', 'using all patients in the analysis population being summarized', '(with randomized or received treatment as/if appropriate) as the', 'denominator.', 'To compare the absolute change in pain from baseline to 4-', 'months, the intra-patient change will be calculated and serve as', 'the dependent variable in the analysis. The baseline pain score', 'will be introduced in the model as a covariate. Clinical site will', 'be added to the model to assess poolability of the data across', 'sites. Interaction between clinical site and treatment will be', 'evaluated using a type 1 error rate of 10%.', 'Treatment-emergent adverse events will be summarized by study', 'part, type, frequency, severity, and relationship to the study', 'device. Adverse events will be provided in a listing.', 'SAS Version 9.4 or later will be used to produce all statistical', 'tables, listings and figures to be contained in the integrated', 'statistical/clinical report.', '710-7105-01 C', 'RBI.2017.002 Version C', 'CONFIDENTIAL']['15', 'Table of Contents', '1.', 'INTRODUCTION AND BACKGROUND', '19', '2.', 'STUDY OBJECTIVES', '24', '3.', 'STUDY DESIGN', '25', '3.1', 'STUDY DESIGN', '25', '3.2.', 'EFFICACY ENDPOINTS', '26', '3.3', 'SAFETY EVALUATION', '26', '3.4', 'ELIGIBILITY CRITERIA', '27', '3.5', 'ENROLLMENT', '30', '3.6', 'RANDOMIZATION', '30', '3.7', 'DEVICE DESCRIPTION', '30', '3.7.1', 'Control Unit', '30', '3.7.2', 'Treatment Applicator', '32', '3.8', 'LOGISTICS AND DEVICE ACCOUNTABILITY', '32', '3.9', 'LABELING', '33', '3.10', 'PREPARATION AND ADMINISTRATION', '33', '3.11', 'BLINDING', '33', '3.12', 'STUDY ASSESSMENTS', '34', '3.12.1', 'Primary Efficacy Assessment', '34', '3.12.2', 'Secondary Efficacy Assessments', '34', '3.12.3 Exploratory Efficacy Assessment', '37', '3.12.4 Additional Study Assessments', '38', '3.12.5 Safety Assessments', '40', '4.', 'STUDY PROCEDURES', '40', '4.1', 'VISIT 1 - SCREENING VISIT (DAY - -15)', '40', '4.2', '14-DAY RUN-IN PERIOD', '42', '4.3', 'VISIT 2 - ENROLLMENT VISIT (DAY 0)', '42', '4.4', 'DAY 7 PHONE CALL (DAY 7 +2 DAYS)', '43', '4.5', '1 MONTH INTERIM VISIT (DAY 30 3 DAYS)', '43', '4.6', '2 MONTH INTERIM VISIT (DAY 60 3 DAYS)', '43', '4.7', '3 MONTH INTERIM VISIT (DAY 90 + 3 DAYS)', '44', '4.8', '4 MONTH END OF PART A VISIT (DAY 121 + 3 DAYS)', '44', '4.9', 'PART B - 5 MONTH PHONE CALL (DAY 150 3 DAYS)', '45', '4.10', 'PART B - 6 MONTH PHONE CALL (DAY 180 3 DAYS)', '45', '4.11', 'PART B - 7 MONTH PHONE CALL (DAY 210 + 3 DAYS)', '45', '4.12', 'PART B - 8 MONTH VISIT (DAY 240 + 3 DAYS)', '46', '4.13', 'PART B - 9 MONTH PHONE CALL (DAY 270 + 3 DAYS)', '46', '4.14', 'PART B - 10 MONTH PHONE CALL (DAY 300 + 3 DAYS)', '46', '4.15', 'PART B - 11 MONTH PHONE CALL (DAY 330 3 DAYS)', '46', '4.16', 'PART B - 12 MONTH END OF STUDY VISIT (DAY 361 3 DAYS)', '47', '710-7105-01 C', 'RBI.2017.002 Version C', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}